股票简称：欧普康视 证券代码：300595 公告编号：2024-060 欧普康视科技股份有限公司 第四届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏 一、监事会会议召开情况 （一）欧普康视科技股份有限公司（以下简称"公司"）第四届监事会第十 次会议，于 2024 年 6 月 14 日以电子通讯及送达的方式发出会议通知。 本议案尚需提交公司股东大会审议。 三、备查文件 （三）本次会议应参与表决监事 3 人，实际参与表决监事 3 人。 （四）会议由监事会主席孙永建先生主持。 （五）本次会议召开符合《公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 经投票表决，会议审议通过如下决议： 以 3 票赞成，0 票反对，0 票弃权审议通过《关于对募集资金投资项目之"接 触镜和配套产品产业化项目"调整内部投资结构、增加实施地点及延期的议案》 经审核，监事会认为本次对该募投项目调整内部投资结构、增加实施地点及 延期是公司根据项目的实际情况做出的审慎决定，不会对募集资金投资项目的实 施产生不利影响，不存在改变或变相改变募集资金投向和损害股东利益 ...

证券代码：300595 证券简称：欧普康视 公告编号：2024-058 欧普康视科技股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）2023 年年度权益分派方 案已获 2024 年 4 月 22 日召开的 2023 年年度股东大会审议通过，现将权益分派 事宜公告如下： 一、股东大会审议通过利润分配方案等情况 1、公司 2023 年度股东大会审议通过的 2023 年年度利润分配方案为：以公 司现有总股本 897,145,269 股为基数，向全体股东每 10 股派发现金红利人民币 2.23 元（含税），合计派发红利 200,063,394.99 元，剩余未分配利润结转以后 年度，本年度不送红股，不以公积金转增股本。 若在本次利润分配方案实施前，公司股本发生变动，公司将以未来实施利润 分配方案的股权登记日的总股本为基数，按照分配比例不变的原则对分配总额进 行调整。 转让股票时，根据其持股期限计算应纳税额【注】；持有首发后限售股、股权激 励限售股及无限售流通股的证券投资基金所涉 ...

股票简称：欧普康视 证券代码：300595 公告编号：2024-057 欧普康视科技股份有限公司 关于持股5%以上股东部分股份补充质押的公告 持股 5%以上的股东南京欧陶信息科技有限公司保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到公司持股 5% 以上的股东南京欧陶信息科技有限公司（以下简称"南京欧陶"）通知，获悉其 所持有公司的部分股份办理了补充质押，现将具体情况公告如下： 注：本公告中所涉数据的尾数差异或不符系四舍五入所致。 一、股东股份质押的基本情况 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本次质押数 量（股） 占其 所持 股份 比例 （%） 占公 司总 股本 比例 (%) 是否 为限 售股 是否 为补 充质 押 质押 起始日 质押 到期日 质权人 质押 用途 南京 欧陶 否 380,000 0.31 0.04 否 是 2024/4/29 办理解除 质押登记 手续之日 招商证券 股份有限 公司 补充 质押 合 ...

Investment Rating - The report maintains a **Cautious Overweight** rating for the company [1][3] - The target price is set at **20.64 CNY**, unchanged from the previous forecast [1][3] Core Views - The company's Q1 2024 performance met expectations, with revenue reaching **4.65 billion CNY (+15.71% YoY)** and net profit attributable to shareholders at **1.93 billion CNY (+11.39% YoY)** [1] - The company's product portfolio is diversified, with **hard contact lenses and care products** showing steady growth, while **medical devices and functional frame glasses** maintained high growth rates [1] - The company's **gross margin** decreased by **2.36 percentage points** in Q1 2024, primarily due to the increased proportion of low-margin products such as frame glasses and medical services [1] - The company has a rich pipeline of **R&D projects**, including next-generation orthokeratology materials, multifocal soft lenses, and eye care products, which are expected to drive future growth [1] Financial Performance - The company's **revenue** for 2024E is projected to be **2,021 million CNY**, with a **16% YoY growth** [1][3] - **Net profit attributable to shareholders** is expected to reach **891 million CNY** in 2025E, with a **15% YoY growth** [1][3] - The **operating profit margin** is forecasted to be **42.4%** in 2024E, slightly down from **43.1%** in 2023A [1][3] - The **ROE** is expected to remain stable at around **15.6%** in 2024E [1][3] Product and Market Analysis - **Hard contact lenses** saw steady growth in Q1 2024, with growth in private channels offsetting declines in public hospital channels [1] - **Care products** stabilized in Q1 2024, with the company's efforts to coordinate online and offline sales channels and promote its own brand showing positive results [1] - **Medical devices and functional frame glasses** continued to experience strong demand, with high growth expected to continue throughout 2024 [1] - The company's **controlled optometry centers** are increasing in number, contributing to incremental growth [1] Valuation and Metrics - The **P/E ratio** for 2024E is projected at **21.81x**, with a **P/B ratio** of **4.66x** [1][3] - The **EV/EBITDA** ratio is expected to decrease to **16.54x** in 2024E, down from **22.26x** in 2023A [1][3] - The **dividend yield** is forecasted to be **1.1%** in 2024E, consistent with 2023A [1][3] Industry and Company Overview - The company is a leader in the **orthokeratology lens** segment in China, focusing on the R&D, production, and sales of eye care products, as well as providing optometry services [3] - The company's core products include **hard contact lenses** and **lens care products**, with orthokeratology lenses being the primary revenue driver [3]

Summary of Conference Call Company/Industry Involved - The conference call involves the pharmaceutical industry, specifically focusing on a company represented by the chief analyst Yuan Wei from International Securities [1]. Core Points and Arguments - The chief analyst addressed investors, indicating a focus on the pharmaceutical sector and its current dynamics [1]. Other Important but Possibly Overlooked Content - No specific financial data, growth percentages, or detailed insights into the company's performance or market conditions were provided in the excerpt [1].

业绩简评 2024 年 4月 26日，公司发布2024 年第一季度报告。2024年 Q1， 公司实现收入4.65 亿元（+15.7%，同比，下同）；归母净利润1.93 亿元（+11.4%）；扣非归母净利润1.67 亿元（+11.6%）。 经营分析 硬镜和护理产品基本持平，控股终端增长良好。分产品来看，2024 年Q1年公司产品销售和医疗服务均实现增长且医疗服务收入增长 较高。产品销售方面，医疗器械和功能性框架镜等非硬镜产品实 现高增长，硬镜和护理产品基本持平。其中，硬镜产品在公司控 股视光终端和民营渠道继续增长，但在公立医院渠道(含公立医院 视光中心）销售收入下滑；护理产品止住去年下滑的趋势且公司 自产护理品的占比大幅提高。渠道方面，公司控股终端的营业收 入增幅高于总体收入增幅，其在总收入中的占比进一步提高。截 至23 年底，公司终端业务在总收入中占比为48.79%，合计控股和 人民币(元) 成交金额(百万元) 参股的视光服务终端已超过 400 家，后续随着公司继续扩展终端 36.00 1,400 数量，看好终端持续为公司业绩增长贡献动力。 1,200 32.00 1,000 销售费用加大，产品结构变化降低毛 ...

Investment Rating - The investment rating for the company is "Buy," consistent with the previous rating of "Buy" [1]. Core Views - The company reported a revenue of 465 million yuan in Q1 2024, representing a year-on-year growth of 15.71%. The net profit attributable to the parent company was 193 million yuan, up 11.39%, while the net profit excluding non-recurring items was 167 million yuan, increasing by 11.59%. The growth rates for revenue and profit are closely aligned [1]. - The core product, OK Mirror, faces strong competition, leading to a stable revenue performance. Factors such as weak consumer spending, increased competition from defocused lenses, and the emergence of new brands have contributed to a decline in industry growth. As a leading company, efforts are being made to stabilize sales through channel acquisitions and market share enhancement [1]. - The company has seen continuous growth in terminal and private channels, while public channel revenues have declined. Nursing products have stopped their downward trend, with a 12.02% decline in revenue for nursing products in 2023. The company has strengthened online channel promotions, resulting in stable revenue in Q1 2024 and a significant increase in the proportion of its own brand, which is expected to enhance gross margins [1]. - The company has been actively acquiring terminals, which has driven growth in medical services and ordinary frame mirror revenues. By the end of 2023, the revenue contribution from controlled subsidiaries accounted for 49% of total revenue, with over 400 controlled terminals established, further advancing chain operations [1]. - The company's gross margin is 76%, down by 2.36 percentage points, primarily due to changes in product mix, with a higher proportion of low-margin medical services and ordinary frame mirrors. The sales expense ratio increased to 23.64%, up by 4.81 percentage points, due to enhanced marketing efforts and increased sales and technical support personnel [1]. - The company has established multiple health-related industry funds, focusing on expanding into the optical and health sectors. Additionally, it is actively exploring other optical tracks, including partnerships for low-concentration atropine and investments in visual training products [1]. Financial Summary - The company is projected to achieve total revenue of 1,525 million yuan in 2024, with a year-on-year growth of 14.1%. The net profit attributable to the parent company is expected to reach 624 million yuan, reflecting a growth of 10.6% [2]. - The gross margin is forecasted to be 74.6% in 2024, slightly decreasing from 74.8% in 2023 [2]. - The projected earnings per share (EPS) for 2024 is 0.70 yuan, with a price-to-earnings (P/E) ratio of 25.97 [2].

股票简称：欧普康视 证券代码：300595 公告编号：2024-056 欧普康视科技股份有限公司 关于2021年限制性股票激励计划首次授予第二个解除限售期 和预留授予第一个解除限售期解除限售条件未成就 暨拟回购注销部分限制性股票的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1 一、限制性股票股权激励计划已履行的相关审批程序 1、2021 年 12 月 15 日，公司召开第三届董事会第十八次会议和第三届监事会 第十七次会议，分别审议并通过了《关于<欧普康视科技股份有限公司 2021 年限制 性股票激励计划（草案）>及其摘要的议案》《关于<欧普康视科技股份有限公司 2021 年限制性股票激励计划考核管理办法>的议案》《关于提请股东大会授权董事会办 理公司 2021 年限制性股票激励计划有关事宜的议案》。公司独立董事对此发表了 独立意见，监事会对本次激励对象名单进行了核实。 特别提示： 1、公司2021年限制性股票激励计划首次授予第二个解除限售期和预留授予第 一个解除限售期解除限售条件均未成就，本次涉及激励对象共有 45 人，其中首次 授予部分 39 人， ...

Financial Performance - The company's revenue for Q1 2024 was CNY 464,528,576.94, representing a 15.71% increase compared to CNY 401,473,749.24 in the same period last year[3] - Net profit attributable to shareholders for Q1 2024 was CNY 192,953,174.53, up 11.39% from CNY 173,217,878.06 year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 166,587,271.85, reflecting an 11.59% increase from CNY 149,290,819.27 in the previous year[3] - Total operating revenue for Q1 2024 reached CNY 464,528,576.94, an increase of 15.7% compared to CNY 401,473,749.24 in Q1 2023[24] - The net profit for Q1 2024 was CNY 211,851,985.06, an increase of 7.1% compared to CNY 197,639,400.47 in Q1 2023[25] - Operating profit for Q1 2024 reached CNY 242,775,318.18, up from CNY 231,054,020.43 in the same period last year, reflecting a growth of 5.5%[25] - The total comprehensive income for Q1 2024 was CNY 216,277,844.28, compared to CNY 197,639,400.47 in the same quarter last year, reflecting an increase of 9.4%[26] Cash Flow and Assets - The company's cash flow from operating activities for Q1 2024 was CNY 196,421,532.75, a 2.20% increase from CNY 192,191,357.35 in the same quarter last year[3] - The company's cash and cash equivalents at the end of the quarter amounted to ¥977,225,355.88, down from ¥1,057,160,297.31 at the beginning of the quarter, representing a decrease of approximately 7.8%[22] - The trading financial assets increased to ¥1,164,311,020.29 from ¥1,004,978,044.59, reflecting a growth of about 15.8%[22] - Accounts receivable rose to ¥278,350,175.02 from ¥241,689,850.56, indicating an increase of approximately 15.1%[22] - Total assets at the end of Q1 2024 were CNY 5,730,114,729.91, which is a 3.83% increase from CNY 5,518,910,590.46 at the end of the previous year[3] - Current assets totaled CNY 3,813,795,583.14, compared to CNY 3,693,983,463.82 in the previous year, indicating a growth of 3.2%[23] - Non-current assets increased to CNY 1,916,319,146.77 from CNY 1,824,927,126.64, representing a growth of 5.1%[23] - Total liabilities decreased to CNY 793,030,614.76 from CNY 807,850,591.94, a reduction of 1.8%[24] - Shareholders' equity increased to CNY 4,937,084,115.15 from CNY 4,711,059,998.52, reflecting a growth of 4.8%[24] Expenses and Costs - Total operating costs for Q1 2024 were CNY 246,507,886.38, up from CNY 194,230,834.44 in the same period last year, reflecting a 27% increase[24] - Sales expenses increased by 45.28% to CNY 109,802,599.13, primarily due to increased personnel costs and expenses related to new store openings[11] - Research and development expenses for the quarter were CNY 39,633,549.60, up from CNY 33,137,770.52, indicating a commitment to innovation[23] - Research and development expenses were CNY 8,116,022.14, slightly higher than CNY 7,861,038.77 in Q1 2023, showing a growth of 3.2%[25] Shareholder Information - The total number of common shareholders at the end of the reporting period was 72,216[14] - Tao Yuequn held 33.32% of the shares, amounting to 298,890,828 shares[14] - Nanjing Outo Information Technology Co., Ltd. owned 13.69% of the shares, totaling 122,790,521 shares[14] - The top ten shareholders accounted for a significant portion of the company's equity, with the largest shareholder holding over 33%[14] - The company did not report any changes in the number of restricted shares during the period[18] Strategic Outlook - The company is focused on enhancing its product offerings and technological advancements[29] - Future outlook includes potential market expansion strategies[29] - The company aims to improve user data analytics for better decision-making[29] - There are plans for new product launches in the upcoming quarters[29] - The company is exploring opportunities for mergers and acquisitions to strengthen its market position[29] - Emphasis on research and development to drive innovation in the industry[29] - The company is committed to maintaining a strong financial position while pursuing strategic acquisitions and partnerships to drive growth[21] - The company is actively managing its liquidity and financial resources to support ongoing operations and future investments[22] Miscellaneous - The first quarter report of Oupinkang Vision Technology Co., Ltd. is unaudited[29] - The report was released on April 27, 2024[29] - The board of directors is committed to maintaining transparency in financial reporting[29] - The company is actively monitoring market trends to adapt its strategies accordingly[29]

股票简称：欧普康视 证券代码：300595 公告编号：2024-053 欧普康视科技股份有限公司 第四届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏 一、监事会会议召开情况 1、欧普康视科技股份有限公司（以下简称"公司"）第四届监事会第九次 会议，于 2024 年 4 月 21 日以电子通讯及送达的方式发出会议通知。 2、会议于 2024 年 4 月 26 日以现场形式召开。 3、本次会议应参与表决监事 3 人，实际参与表决监事 3 人。 4、本次会议召开符合《公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 经投票表决，会议审议通过如下决议： (一)以 3 票赞成，0 票反对，0 票弃权审议通过《欧普康视科技股份有限公 司 2024 年第一季度报告》 经审核，监事会认为:董事会编制和审核公司 2024 年第一季度报告的程序符 合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公 司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 1 (三) 以 3 票赞成，0 票反对，0 票弃权审议通过《关于调整 ...